OP-1118 (Fidaxomicin metabolite OP-1118) is an orally effective dual inhibitor of NF-kappaB and ERK1/2, with low systemic plasma exposure, no accumulation, and primary excretion via feces. By inhibiting the phosphorylation of NF-kappaB and ERK1/2 and reducing the expression of pro-inflammatory cytokines, OP-1118 exerts significant anti-inflammatory, cytoprotective, anti-apoptotic and antibacterial activities. In Clostridium difficile infection models, OP-1118 effectively blocks toxin-mediated intestinal inflammation, cell rounding, histological damage and apoptosis, and its protective effect can be reversed by PMA (HY-18739)[1][2][3].
Molekulargewicht:
987.95
CAS Nummer:
[1030825-28-5]
Formel:
C48H68Cl2O17
Target-Kategorie:
Apoptosis,Bacterial,ERK,NF-kappaB
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
